Re‐analysis of stratified samples of diverse liver diseases from GSE89377 and GSE6764 further supported a potential role for SF3B4 as a key driver in HCC progression (Figure 5C).[22] In support of our hypothesis, circAtlas 2.0 (January 2024 snapshot, Figure S4C, Supporting Information) predicted SF3B4 binding within the flanking region of circSMEK1. Here, SF3B4 is linked to hepatocellular carcinoma.